Results 61 to 70 of about 35,256 (161)

Evaluating the Therapeutic Potential of Ublituximab in the Treatment of MS: Design, Development and Place in Therapy

Drug Design, Development and Therapy
Sarah-Jane Martin,1,2 Melanie Guenette,1 Jiwon Oh1 1Division of Neurology, Department of Medicine, St Michael’s Hospital, Toronto, Canada; 2University of Glasgow, Glasgow, UKCorrespondence: Jiwon Oh, Email jiwon.oh@unityhealth.toAbstract: B cells are ...
Martin SJ, Guenette M, Oh J
doaj  

Impact of Treatment with Anti-CD20 Monoclonal Antibody on the Production of Neutralizing Antibody Against Anti-SARS-CoV-2 Vaccination in Mature B-Cell Neoplasms. [PDF]

Infect Drug Resist, 2023
Onishi A, Matsumura-Kimoto Y, Mizutani S, Tsukamoto T, Fujino T, Miyashita A, Nishiyama D, Shimura K, Kaneko H, Kawata E, Takahashi R, Kobayashi T, Uchiyama H, Uoshima N, Nukui Y, Shimura Y, Inaba T, Kuroda J.   +17 more
europepmc   +1 more source

The use of monoclonal antibody (Rituximab) in the treatment of type II mixed cryoglobulinemia

Brazilian Journal of Infectious Diseases
Anti-CD20 monoclonal antibody has been successfully used to treat several self-immune diseases. The authors report the case of a 71 year-old female patient under the use of pegylated form of interferon á associated with ribavirin for the treatment of ...
Thiago Carlos Gonçalves Rego, Celso Mitsushi Massumoto, Rodrigo Siqueira Batista, Larissa Hanauer de Moura, Lygia Maria Costa Soares, Andréia Patrícia Gomes   +5 more
doaj   +1 more source

Cure of Micrometastatic B-Cell Lymphoma in a SCID Mouse Model Using ²¹³Bi-Anti-CD20 Monoclonal Antibody. [PDF]

J Nucl Med, 2023
Havlena GT, Kapadia NS, Huang P, Song H, Engles J, Brechbiel M, Sgouros G, Wahl RL.   +7 more
europepmc   +1 more source

Anti-CD20 Monoclonal Antibody [PDF]

, 2020
openaire   +1 more source

CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies

OncoImmunology
Rituximab (RTX) plus chemotherapy (R-CHOP) applied as a first-line therapy for lymphoma leads to a relapse in approximately 40% of the patients. Therefore, novel approaches to treat aggressive lymphomas are being intensively investigated.
Malgorzata Bobrowicz, Aleksandra Kusowska, Marta Krawczyk, Andriy Zhylko, Christopher Forcados, Aleksander Slusarczyk, Joanna Barankiewicz, Joanna Domagala, Matylda Kubacz, Michal Šmída, Lenka Dostalova, Katsiaryna Marhelava, Klaudyna Fidyt, Monika Pepek, Iwona Baranowska, Anna Szumera-Cieckiewicz, Else Marit Inderberg, Sébastien Wälchli, Monika Granica, Agnieszka Graczyk-Jarzynka, Martyna Majchrzak, Marcin Poreba, Carina Lynn Gehlert, Matthias Peipp, Malgorzata Firczuk, Monika Prochorec-Sobieszek, Magdalena Winiarska   +26 more
doaj   +1 more source

Anti-CD20 Monoclonal Antibody TL011 [PDF]

, 2020
openaire   +1 more source

Anti-CD20 Monoclonal Antibody SCT400 [PDF]

, 2020
openaire   +1 more source

Case Report: Successful treatment of severe pneumocystis carinii pneumonia in a case series of primary nephrotic syndrome after receiving anti-CD20 monoclonal antibody therapy. [PDF]

Front Pediatr, 2022
Liu L, Zheng W, Wang P, Wu Y, Zhu G, Yang R, Gu L, Huang W, Kang Y.   +8 more
europepmc   +1 more source

Anti-CD20 Monoclonal Antibody B001 [PDF]

, 2020
openaire   +1 more source